Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Elevai Labs, Inc. Common Stock (ELAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.47M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 290432 | Beta - | 52 Weeks Range 3.88 - 1064.00 | Updated Date 04/6/2025 |
52 Weeks Range 3.88 - 1064.00 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -50.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.4% | Return on Equity (TTM) -76.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3798794 | Price to Sales(TTM) 2.34 |
Enterprise Value -3798794 | Price to Sales(TTM) 2.34 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA - | Shares Outstanding 577000 | Shares Floating 634232 |
Shares Outstanding 577000 | Shares Floating 634232 | ||
Percent Insiders 0.95 | Percent Institutions 10.46 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elevai Labs, Inc. Common Stock
Company Overview
History and Background
Elevai Labs, Inc. focuses on developing and marketing physician-dispensed skincare products. Founded with the goal of leveraging scientific advancements to improve skin health, the company emphasizes aesthetic dermatology solutions. Recent milestones include expanding product lines and building partnerships with medical professionals.
Core Business Areas
- Skincare Products: Develops and markets a range of skincare products targeting skin rejuvenation, anti-aging, and overall skin health. The products are formulated with advanced ingredients and designed for use in conjunction with professional aesthetic treatments.
- Professional Partnerships: Collaborates with dermatologists and other medical professionals to distribute and promote their products, focusing on building a network of physician-dispensing practices.
Leadership and Structure
Information on leadership team and organizational structure is not readily available.
Top Products and Market Share
Key Offerings
- Elevai Exosomes: A key product, Elevai Exosomes are used in skin rejuvenation. Market share data is not publicly available. Competitors include companies offering similar exosome-based skincare solutions, such as Benev Company Inc. and Kimera Labs.
- Elevai E-Series: A skincare line, includes products aimed at post-procedure care and overall skin health. Market share data is not publicly available. Competitors include ZO Skin Health and Alastin Skincare.
Market Dynamics
Industry Overview
The aesthetic dermatology market is growing, driven by increasing consumer demand for non-invasive cosmetic procedures and advanced skincare products. Trends include a focus on personalized skincare, the use of advanced technologies (e.g., exosomes), and a growing emphasis on scientifically-backed ingredients.
Positioning
Elevai Labs positions itself as a provider of scientifically advanced skincare products specifically for physician-dispensed channels. Their competitive advantage lies in their focus on exosome technology and their partnerships with medical professionals.
Total Addressable Market (TAM)
The global aesthetic medicine market is projected to reach hundreds of billions USD, and Elevai is positioned in the skincare segment with a potentially high growth rate. However specific TAM size data for Elevai in the aesthetics skincare is not publicly available.
Upturn SWOT Analysis
Strengths
- Innovative exosome technology
- Focus on physician-dispensed channels
- Strong brand reputation within its niche
Weaknesses
- Limited brand awareness compared to larger skincare companies
- Reliance on a specific technology (exosomes) which may face regulatory hurdles
- Limited market share in the broader skincare market
Opportunities
- Expanding product lines to address new skincare concerns
- Increasing partnerships with dermatologists and aesthetic practices
- Entering new geographic markets
Threats
- Increased competition from established skincare brands
- Regulatory changes impacting exosome-based products
- Economic downturn affecting consumer spending on aesthetic treatments
Competitors and Market Share
Key Competitors
- ZO Skin Health (Private)
- Alastin Skincare (Private)
- Benev Company Inc. (Private)
- Kimera Labs (Private)
Competitive Landscape
Elevai Labs faces competition from established skincare brands with greater brand recognition and market reach. Their advantage lies in their focus on exosomes and physician-dispensed channels. They need to continue to establish a strong brand and broaden its distribution network.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Data on historical growth is not publicly available.
Future Projections: Data on future projections is not publicly available.
Recent Initiatives: Recent initiatives include expanding product lines and strengthening partnerships with medical professionals.
Summary
Elevai Labs is a company focused on innovative skincare products, specifically utilizing exosomes in physician-dispensed channels. They hold potential in the aesthetic dermatology market given the consumer demand for scientifically backed products. However, the company has lower brand awareness and needs to strategically build partnerships to expand market share, considering increased competition. Regulatory risks associated with exosome-based products are a point to watch out for.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
EW
Edwards Lifesciences Corp
EW
Edwards Lifesciences Corp
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
ZBH
Zimmer Biomet Holdings Inc
ZBH
Zimmer Biomet Holdings Inc
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Market analysis reports
Disclaimers:
The information provided is based on publicly available data and may not be comprehensive. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elevai Labs, Inc. Common Stock
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2023-11-21 | CEO, CFO, Secretary & Director Mr. Graydon Bensler C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://pmgcholdings.com |
Full time employees 2 | Website https://pmgcholdings.com | ||
PMGC Holdings Inc., a skincare development company, designs, manufactures, and markets skincare products in the United States. The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. It serves dermatologists, plastic surgeons, medical spa owners, and physicians focused on aesthetic and therapeutic skincare. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.